Detection, avoidance and treatment of late effects in the follow-up of children and adolescents with cancer;Spätfolgen in der nachsorge von krebskranken kindern und jugendlichen

Onkologe

Volumn 11, Issue 10, 2005, Pages 1101-1109

  Langer, T ^a   Dorr H G ^a   Bielack, S ^b   Jurgens H ^b   Gobel U ^c   Willich, N ^b   Beck, J D ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Cardiotoxicity; Endocrinological disturbances; Late effects; Nephrotoxicity; Ototoxicity

Indexed keywords

ALPHA INTERFERON; ANTHRACYCLINE; ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BICARBONATE; BISPHOSPHONIC ACID DERIVATIVE; BRONCHODILATING AGENT; CALCIUM; CISPLATIN; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ESTROGEN; GESTAGEN; GLUCOCORTICOID; GONADORELIN DERIVATIVE; GROWTH HORMONE; HYDROCORTISONE; IFOSFAMIDE; MAGNESIUM; PHOSPHATE; RIBAVIRIN; TESTOSTERONE; THYROXINE; VITAMIN D;

ADOLESCENT; AFTERCARE; ARTICLE; CANCER; CANCER THERAPY; CARDIOMYOPATHY; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CHILDHOOD CANCER; COGNITIVE THERAPY; ENDOCRINE DISEASE; EWING SARCOMA; FANCONI RENOTUBULAR SYNDROME; FOLLOW UP; HEARING LOSS; HEART TRANSPLANTATION; HEPATITIS C; HORMONE SUBSTITUTION; HOSPITAL PHYSICIAN; HUMAN; HYPOTHYROIDISM; INFERTILITY; KIDNEY TUBULE DISORDER; LUNG TOXICITY; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; NEPHROTOXICITY; NEUROLOGIC DISEASE; OSTEOPOROSIS; OSTEOSARCOMA; PHYSIOTHERAPY; PRACTICE GUIDELINE; PROSPECTIVE STUDY; PSYCHOTHERAPY; SOFT TISSUE SARCOMA; THYROID DISEASE;

EID: 30444448069     PISSN: 09478965     EISSN: 14330415     Source Type: Journal    
DOI: 10.1007/s00761-005-0933-2     Document Type: Article

References (38)

1. Abrahamsen AF, Loge JH, Hannisdal E, Nome O, Lund MB, Holte H, Kvaloy S (1999) Late medical sequelae after therapy for supradiaphragmatic Hodgkin's disease. Acta Oncol 38:511-515
2. Beck JD, Winkler K, Niethammer D et al. (1995) Die Nachsorge der von einer Krebserkrankung geheilten Kinder und jungen Erwachsenen. Erste Empfehlungen der Arbeitsgemeinschaft Spätfolgen. Klin. Pädiatr. 207:186-192.
3. Beck JD, Dörr HG, Langer T, Bielack SS, Rossi R, Gutjahr P (1999) In: Schmoll HJ, Höffken K, Possinger K (Hrsg) Spätfolgen der antineoplastischen Behandlung im Kindesalter. Die Nachsorge der von einer Krebserkrankung geheilten Kinder und Jugendlichen. Kompendium Internistische Onkologie. Springer, Berlin Heidelberg New York, S 1462-1479
4. Blatt J, Copeland DR, Bleyer A (1997) Late effects of childhood cancer and its treatment. Principles and practice of pediatric oncology, third edition, edited by Philip A. Pizzo and David G. Poplack. Lippincott-Raven Publishers, Philadelphia, pp 1303-1329
5. Burger B, Beier R, Zimmermann M, Beck JD, Reiter A, Schrappe M (2005) Osteonecrosis: a treatment related toxicity in childhood acute lymphoblastic leukemia (ALL) - experiences from trial ALL-BFM 95. Pediatr Blood Cancer 44:220-225
6. Clayton PE, Shalet SM (1991) Dose dependency of time of onset of radiation-induced growth hormone deficiency. J Pediatr 118:226-228
7. Creutzig U, Henze G, Bielack S et al. (2003) Krebserkrankungen bei Kindern - Erfolg durch einheitliche Therapiekonzepte seit 25 Jahren. Dtsch Arztebl 100:A842-852
8. Creutzig U, Zimmermann M, Hannemann J, Kramer I, Herold R, Henze G (2003) Quality management within the competence network of paediatric oncology and haematology. Klin Padiatr 215:338-340
9. Creutzig U, Jurgens H, Herold R, Gobel U, Henze G (2004) Concepts of the Society of Paediatric Oncology and Haematology (GPOH) and the German Competence Network in Paediatric Oncology and Haematology for the quality controlled development in paediatric oncology. Klin Padiatr 216:379-383
10. Crom DB, Kaste SC,Tubergen DG, Greenwald CA, Sharp GB, Hudson MM (1997) Ultrasonography for thyroid screening after head and neck irradiation in childhood cancer survivors. Med Pediatr Oncol 28:15-21
11. Göbel U, Jürgens H (2003) Transferring disease-oriented basic research into pediatric oncology. Klin Padiatr 215-6: 289-290
12. Göbel U, Kulozik AE (2004) Scientific results in paediatric oncology and haematology. Klin Padiatr 216:301-303
13. Green DM, D'Angio GJ (1992) Late effects of treatment for childhood cancer. Wiley-Liss, New York Chichester Brisbane Torronto Singapore
14. Hertzberg H, Huk WJ, Ueberall MA et al. (1997) CNS late effects after ALL therapy in childhood. Part I: Neuroradiological findings in long-term survivors of childhood ALL - an evaluation of the interferences between morphology and neuropsychological performance. The German Late Effects Working Group. Med Pediatr Oncol 28:387-400
15. Jakacki RI, Schramm CM, Donahue BR, Haas F, Allen JC (1995) Restrictive lung disease following treatment for malignant brain tumors: a potential late effect of craniospinal irradiation. J Clin Oncol 13:1478-1485
16. Kaatsch P, Blettner M, Spix C, Jurgens H (2005) Follow up of long-term survivors after childhood cancer in Germany. Klin Padiatr 217:169-175
17. Klein G, Michaelis J, Spix C, Wibbing R, Eggers G, Ritter J, Kaatsch P (2003) Second malignant neoplasms after treatment of childhood cancer. Eur J Cancer 39:808-817
18. Kusch M, Labouvie H, Langer T et al. (1999) Psychosoziale Folgen von Krebs im Kindes- und Jugendalter: Empirisch fundierte Erkenntnisse und begründbarer rehabilitativer Bedarf. Versorgungsmanagement in Theorie und Praxis, Bd 4. Empirische Pädagogik, Landau, S 1-148
19. Langer T, Henze G, Beck JD (2000) Basic methods and the developing structure of a late effects surveillance system (LESS) in the long-term follow-up of pediatric cancer patients in Germany. For the German Late Effects Study Group in the German Society Pediatric Oncology and Hematology (GPOH). Med Pediatr Oncol 34:348-351
20. Langer T, Führer M, Stöhr W et al. (2002) Die Überlebenden einer Krebserkrankung im Kindesalter. Nachsorge und Spätfolgen nach erfolgreicher Therapie. Monatsschr Kinderheilkd 150:942-953
21. Langer T, Martus P, Ottensmeier H, Hertzberg H, Beck JD, Meier W (2002) CNS late-effects after ALL-therapy in childhood Part III: Neuropsychological performance in long-term survivors of childhood ALL. Impairments of distractibility, attention and memory and its interferences to CNS morphology. Med Pediatr Oncol 38:320-332
22. Langer T, Zepf K, Krappmann P, Gravou-Apostolatou Ch, Beck JD (2003) In: Hiddemann W et al. (eds) Prospective, multicenter study of CNS-toxicity and health-related quality of life in ALL-patients. Acute leukemias IX. Basic research, experimental approaches and novel therapies. Springer, Berlin Heidelberg New York, pp 445-450
23. Langer T, Stöhr W, Bielack S, Paulussen M, Treuner J, Beck JD (2004) Late effects surveillance system for sarcoma patients. Pediatr Blood Cancer 42:373-379
24. Langer T, Stohr W, Paulides M, Kremers A, Dorr HG, Gobel U, Beck JD (2005) Prospective Multicenter Registration of Major Late Sequelae in Sarcoma Patients Using the Late Effects Surveillance System (LESS). Klin Padiatr 217:176-181
25. Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD, Colan SD (2005) Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 23:2629-2636
26. Lorenz M, Graf N, Konig J, Ruprecht KW, Kasmann-Kellner B (2002) Eye findings in paediatric brain tumour - data basis for a follow-up proposal. Klin Padiatr 214:117-125
27. Marx M, Beck JD, Müller HL, Kühl J, Langer T, Dörr HG (2000) Endocrine late-effects of brain tumour therapy in childhood and adolescence: concept of a prospective endocrinological follow-up. Klin Padiatr 212:224-228
28. Marx M, Langer T, Graf N, Hausdorf G, Stöhr W, Ludwig R, Beck JD (2002) Multicentre analysis of anthracycline-induced cardiotoxicity in children following treatment according to the nephroblastoma studies SIOP no.9/GPOH and SIOP 93-01/GPOH. Med Pediatr Oncol 39:18-24
29. Moller TR, Garwicz S, Barlow L, Falck Winther J, Glattre E, Olafsdottir G, Olsen JH, Perfekt R, Ritvanen A, Sankila R, Tulinius H (2001) TI - Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries. J Clin Oncol 19:3161-3162
30. Neglia JP, Meadows AT, Robinson LL et al. (1991) Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med 325:1330-1336
31. Ochs J, Mulhern R, Fairdough D, Parvey L, Whitaker J, Ch'ien L, Mauer A, Simone J (1991) Comparison of neuropsychologic functioning and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial radiation or parenteral methotrexate: a prospective study. J Clin Oncol 9:145-151
32. O'Driscoll BR, Hasleton PS, Taylor PM, Poulter LW, Gattameneni HR, Woodcock AA (1990) Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. N Engl J Med 323:378-382
33. Rossi R, Kleinebrand A, Gödde A, Rath B, Jürgens H (1993) Increased risk of ifosfamide-induced renal Fanconi's syndrome after unilateral nephrectomy. Lancet (letter to the editor) 341:755
34. Schellong G, Riepenhausen M (2004) Late effects after therapy of Hodgkin's disease: update 2003/04 on overwhelming post-splenectomy infections and secondary malignancies. Klin Padiatr 216:364-369
35. Skinner R, Pearson AD, English MW, Price L, Wyllie RA, Coulthard MG, Craft AW (1998) Cisplatin dose rate as a risk factor for nephrotoxicity in children. Br J Cancer 77:1677-1682
36. Stöhr W, Langer T, Kremers A, Brecht I, Treuner J, Dinnesen A, Beck JD (2004) Hearing function in soft tissue sarcoma patients after treatment with carboplatin: A report from the Late Effects Surveillance System. Oncol Rep 12:767-771
37. Stöhr W, Langer T, Kremers A, Bielack S, Lamprecht-Dinnesen A, Frey E, Beck JD (2005) Cisplatin-induced ototoxicity in osteosarcoma patients: A report from the Late effects Surveillance System. Cancer Invest (in press)
38. Überall MA, Wenzel D, Hertzberg H et al. (1997) CNS late-effects after ALL therapy in childhood Part II: Conventional EEG recordings in asymptomatic long-term survivors of childhood ALL. An evoluation of the interferences between neurophysiology, neurology, psychology and CNS morphology. Med Pediatr Oncol 29:121-131